FRANK DANIEL 4
4 · Molecular Insight Pharmaceuticals, Inc. · Filed May 14, 2009
Insider Transaction Report
Form 4
FRANK DANIEL
Director
Transactions
- Award
Stock option (right to buy)
2009-05-12+25,000→ 25,000 totalExercise: $3.93From: 2010-05-12Exp: 2019-05-12→ Common Stock, par value $0.01 per share (25,000 underlying)
Footnotes (3)
- [F1]Daniel Frank is a director of Molecular Insight Pharmaceuticals, Inc. (the "Company"). Effective May 12, 2009, Mr. Frank was granted a Non-Qualified Stock Option (the "Option") to buy 25,000 shares of the Company's common stock at $3.93 per share. The 25,000 shares vest on May 12, 2010. The Option expires on May 12, 2019.
- [F2]Mr. Frank owns (i) 143,280 shares of the common stock of the Company, par value $0.01 per share (the "Shares"), (ii) stock options to purchase 4,166 Shares at an exercise price of $4.80 per Share, (iii) stock options to purchase 25,000 Shares at an exercise price of $12.16 per Share, (iv) stock options to purchase 25,000 Shares at an exercise price of $8.20 per Share and (v) stock options to purchase 25,000 Shares at an exercise price of $3.93 per Share. Mr. Frank is a Managing Director of Cerberus Capital Management, L.P., an affiliate of which, Cerberus Partners, L.P., owns certain securities of the Company, all of which are subject to the sole voting and investment authority of Stephen Feinberg. Mr. Feinberg, in his capacity as the holder of sole voting and investment authority of more than 10.0% of the Shares pursuant to Reg. 13d-3, separately files statements pursuant to Sections 13 and 16 of the Securities Exchange Act of 1934, as amended.
- [F3]Mr. Frank does not exercise any voting, investment or other authority with respect to the Shares separately reported by Mr. Feinberg and he disclaims beneficial ownership thereof.